HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Given Average Recommendation of “Hold” by Brokerages

Shares of HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) have been given an average rating of “Hold” by the five research firms that are covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, one has given a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $15.30.

Several brokerages have weighed in on HCM. Weiss Ratings downgraded HUTCHMED from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, June 29th. Morgan Stanley set a $13.60 price objective on shares of HUTCHMED in a report on Thursday, May 28th. Finally, Bank of America decreased their price objective on shares of HUTCHMED from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Tuesday.

HUTCHMED Stock Down 1.3%

Shares of HCM stock opened at $10.98 on Friday. HUTCHMED has a 1-year low of $9.77 and a 1-year high of $19.50. The stock’s fifty day moving average price is $11.49 and its 200 day moving average price is $13.50. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.83 and a current ratio of 4.96.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in HCM. Blue Trust Inc. lifted its stake in shares of HUTCHMED by 131.5% during the fourth quarter. Blue Trust Inc. now owns 7,708 shares of the company’s stock worth $103,000 after buying an additional 4,378 shares during the period. Ameriprise Financial Inc. raised its stake in HUTCHMED by 4.7% in the 2nd quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock worth $234,000 after acquiring an additional 698 shares during the last quarter. Bank of America Corp DE raised its stake in HUTCHMED by 17.3% in the 2nd quarter. Bank of America Corp DE now owns 20,582 shares of the company’s stock worth $310,000 after acquiring an additional 3,035 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in HUTCHMED by 34.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 21,721 shares of the company’s stock worth $342,000 after acquiring an additional 5,538 shares during the period. Finally, Janney Montgomery Scott LLC acquired a new stake in HUTCHMED during the 1st quarter worth about $365,000. Hedge funds and other institutional investors own 8.82% of the company’s stock.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.